Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03907475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03907475 · ClinicalTrials.gov record · last posted 2026-07-24

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

StatusRecruiting
PhasePhase 2
Started2019-07-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase II trial studies the side effects of durvalumab when given together with chemotherapy in treating patients with solid tumors that have spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, capecitabine, carboplatin, paclitaxel, and nab-paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with durvalumab may improve how immune cells respond and attack tumor cells.

Protocol amendment history 2 changes detected by DataLookout

2026-06-12
Primary completion pushed: 2026-06-01 → 2027-06-01
2026-06-12
Completion pushed: 2026-06-01 → 2027-06-01
Trial Details
NCT Number NCT03907475
Lead Sponsor National Cancer Institute (NCI)
Conditions Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Enrollment 115 participants
Start Date 2019-07-16
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24